Latest Lipoprotein Stories
Primary efficacy endpoints met in two trials of alirocumab administered every four weeks TARRYTOWN, N.Y. and PARIS, Jan. 9, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
Periodontal disorders such as tooth loss and gingivitis have been identified as a potential risk marker for cardiovascular disease in a large study reported today.
In an analysis of almost 11,000 patients, an assessment of equations that help guide whether a patient should begin taking a statin (cholesterol lowering medication) found that observed and predicted 5-year atherosclerotic cardiovascular disease risks were similar, suggesting that these equations are helpful for clinical decision making.
Kalen Biomedical, LLC (http://www.kalenbiomed.com) is pleased to announce a distribution agreement with MRTeck Co.
Researchers at the University of Copenhagen, Rigshospitalet and Herlev Hospital have identified a clear link between narrowed heart valves and a special lipoprotein in the blood.
In a randomized trial that included about 2,000 patients with or at high risk of cardiovascular disease (CVD), use of a fixed-dose combination medication for blood pressure, cholesterol, and platelet control compared to usual care resulted in significantly improved medication adherence after 15 months and small improvements in systolic blood pressure and low-density lipoprotein cholesterol.
- A person who stands up for something, as contrasted to a bystander who remains inactive.
- One of the upright handlebars on a traditional Inuit sled.